|Application:||IHC-P, IHC-F, ICC, WB|
Data & Images
|Product Name||Anti-VEGFR2/KDR Antibody|
|Description||Rabbit IgG polyclonal antibody for Vascular endothelial growth factor receptor 2(KDR) detection. Tested with WB, IHC-P, IHC-F, ICC in Human.|
|Cite This Product||Anti-VEGFR2/KDR Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # PA1989)|
|Replacement Item||This antibody may replace the following items: sc-28832|sc-530|sc-74483 from Santa Cruz Biotechnology.|
|Application||IHC-P, IHC-F, ICC, WB
*Our Boster Guarantee covers the use of this product in the above tested applications.
**For positive and negative control design, consult "Tissue specificity" under Protein Target Info.
|Recommended Detection Systems||Boster recommends Enhanced Chemiluminescent Kit with anti-Rabbit IgG (EK1002) for Western blot, and HRP Conjugated anti-Rabbit IgG Super Vision Assay Kit (SV0002-1) for IHC(P), IHC(F) and ICC.
*Blocking peptide can be purchased at $50. Contact us for more information
**Boster also offers various secondary antibodies for Immunoflourescecne and IHC. Take advantage of the buy 1 primary antibody get 1 secondary antibody for free promotion for the entire year 2017!
|Immunogen||A synthetic peptide corresponding to a sequence in the middle region of human VEGF Receptor 2(454-469aa HHIHWYWQLEEECANE).|
|Cross Reactivity||No cross reactivity with other proteins|
|Contents||Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.
*carrier free antibody available upon request.
|Concentration||Add 0.2ml of distilled water will yield a concentration of 500ug/ml.|
|Storage||At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time.Avoid repeated freezing and thawing.|
|Purification||Immunogen affinity purified.|
Protein Target Info (Source: Uniprot.org)
You can check the tissue specificity below for information on selecting positive and negative control.
|Protein Name||Vascular endothelial growth factor receptor 2|
|Molecular Weight||151527 MW|
|Protein Function||Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. .|
|Tissue Specificity||Detected in cornea (at protein level). Widely expressed. .|
|Sequence Similarities||Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.|
|Subcellular Localization||Cell junction . Endoplasmic reticulum . Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). .|
|Alternative Names||Vascular endothelial growth factor receptor 2;VEGFR-2;220.127.116.11;Fetal liver kinase 1;FLK-1;Kinase insert domain receptor;KDR;Protein-tyrosine kinase receptor flk-1;CD309;KDR;FLK1, VEGFR2;|
|Research Areas|||cardiovascular|angiogenesis|growth factors|vegf|vegf receptors| microbiology|interspecies interaction|host virus interaction| signal transduction|protein phosphorylation|tyrosine kinases|receptor tyrosine kinases|growth factors/hormones| stem cells|hematopoietic progenitors|surface molecules| cancer|invasion/microenvironment|angiogenic growth factors|oncoproteins/suppressors|oncoproteins|growth factor receptors|endothelial progenitors|endothelial markers|cancer metabolism|response to hypoxia| cardiovascular|cardiovascular markers|cell markers|endothelial cells| metabolism|pathways and processes|metabolism processes||
Background for Vascular endothelial growth factor receptor 2
Dilution Ratios/Recommended Concentrations
At Boster we strive to provide the best Anti-VEGFR2/KDR Antibody by testing all applications on non-spiked tissues and cell lines to ensure that the affinity of the antibody is enough to react to the endogenouse level of the target protein. Read more about our QC panel here.
|Recommended dilution ratios are listed below:|
Immunocytochemistry , 0.5-1μg/ml, Human, -|
Immunohistochemistry(Frozen Section), 0.5-1μg/ml, Human, -
Immunohistochemistry(Paraffin-embedded Section), 0.5-1μg/ml, Human, By Heat
Western blot, 0.1-0.5μg/ml, Human
**Boster provides high sensitivity secondary antibody kits for Western blotting and IHC. For more info see Related Products below.
Anti-VEGFR2/KDR Antibody Images
Click the images to enlarge.
WB: SMMC Cell Lysate
IHC(P): Human Lung Cancer Tissue
ICC: HELA Cell
IHC(F): Human Placenta Tissue
1. Post-translational modification:phosphorylation, methylation, glycosylation etc. These modifications prevent SDS molecules from binding to the target protein and thus make the band size appear larger than expected
2. Post-translational cleavage: this can cause smaller bands and or multiple bands
3. Alternative splicing: the same gene can have alternative splicing patterns generating different size proteins, all with reactivities to the antibody.
4. Amino Acid R chain charge: SDS binds to positive charges. The different size and charge of the Amino Acid side chains can affect the amount of SDS binding and thus affect the observed band size.
5. Multimers: Multimers are usually broken up in reducing conditions. However if the interactions between the multimers are strong, the band may appear higher.,